News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
UK’s National Institute for Clinical Excellence (NICE) Rejects Roche’s Avastin In Breast Cancer
July 9, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON (Reuters) – Roche's blockbuster cancer drug Avastin has been spurned once again by Britain's health cost watchdog NICE, this time as a treatment for breast cancer.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
Roche
MORE ON THIS TOPIC
Podcast
Prasad Out at FDA, Lawmaker Takes Action on Rare Disease Rejections and a Spate of Obesity Data
March 11, 2026
·
1 min read
·
Heather McKenzie
Rare diseases
Senator Ron Johnson Launches Investigation Into FDA Rare Disease Rejections
March 10, 2026
·
3 min read
·
Heather McKenzie
Manufacturing
FDA Sets Scope for Attempt To Reduce Manufacturing-Related Approval Rejections
March 10, 2026
·
2 min read
·
Nick Paul Taylor
Insights
Single Pivotal Trials Demand Stronger Data and Risk Strategies
March 10, 2026
·
3 min read
·
Jennifer C. Smith-Parker
